Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a strong sell rating to a sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

VNDA has been the topic of several other reports. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a research report on Monday, October 5th. Oppenheimer initiated coverage on Vanda Pharmaceuticals in a report on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 target price on the stock. Zacks Research cut Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Thursday, October 15th. Finally, B. Riley Financial reiterated a “buy” rating and set a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research note on Monday, August 10th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.50.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA opened at $3.88 on Friday. The company’s fifty day moving average is $4.76 and its 200-day moving average is $6.20. Vanda Pharmaceuticals has a 12 month low of $3.70 and a 12 month high of $9.94. The firm has a market cap of $234.58 million, a price-to-earnings ratio of -0.84 and a beta of 0.69. The company has a quick ratio of 1.60, a current ratio of 1.61 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.31. Vanda Pharmaceuticals had a negative net margin of 119.87% and a negative return on equity of 58.37%. The business had revenue of $69.81 million for the quarter, compared to the consensus estimate of $69.20 million. Equities analysts expect that Vanda Pharmaceuticals will post -2.68 EPS for the current fiscal year.

Institutional Trading of Vanda Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of VNDA. BlackRock Inc. acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at about $46,841,000. Renaissance Technologies LLC increased its stake in shares of Vanda Pharmaceuticals by 11.2% in the first quarter. Renaissance Technologies LLC now owns 3,759,559 shares of the biopharmaceutical company’s stock worth $25,979,000 after purchasing an additional 378,598 shares during the period. State Street Corp increased its stake in shares of Vanda Pharmaceuticals by 16.6% in the second quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company’s stock worth $21,520,000 after purchasing an additional 500,843 shares during the period. AIGH Capital Management LLC lifted its position in shares of Vanda Pharmaceuticals by 37.6% during the 1st quarter. AIGH Capital Management LLC now owns 2,750,000 shares of the biopharmaceutical company’s stock worth $19,002,000 after purchasing an additional 751,569 shares during the last quarter. Finally, Quantinno Capital Management LP lifted its position in shares of Vanda Pharmaceuticals by 25.0% during the 1st quarter. Quantinno Capital Management LP now owns 327,193 shares of the biopharmaceutical company’s stock worth $2,261,000 after purchasing an additional 65,391 shares during the last quarter. 88.14% of the stock is currently owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.